Cargando…
OR25-01 Durable CYP21A2 Gene Therapy in Non-Human Primates for Treatment of Congenital Adrenal Hyperplasia
Severe Congenital Adrenal Hyperplasia (CAH) is most commonly caused by genetic defects in the CYP21A2 gene, which leads to a deficiency of 21-hydroxylase enzyme and disruption in the biosynthesis of Adrenal corticosteriods. Despite treatment with corticosteroids, patients remain at significant risk...
Autores principales: | Eclov, Rachel J, Lewis, Terra E W, Kapadia, Mayank, Scott, David W, McCoy, Daniel D, Rouse, Jeremy L, Romero, Kirsten B, Beard, Clayton W, Mansfield, Gary S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209390/ http://dx.doi.org/10.1210/jendso/bvaa046.899 |
Ejemplares similares
-
SUN-204 Case of Non-Classic Congenital Adrenal Hyperplasia with Compound CYP21A2 Mutations Combined with CYP11B1 Mutation
por: Salameh, Rami, et al.
Publicado: (2020) -
Large Bilateral Adrenal Myelolipomas in the Setting of Congenital Adrenal Hyperplasia
por: Anderson, Karolina E, et al.
Publicado: (2021) -
An Unusual Case of Bilateral Adrenal Hyperplasia
por: De Castro, Alicia, et al.
Publicado: (2021) -
MON-171 Characterization of the Adrenal Gland and Adrenal Rest Tissues in Congenital Adrenal Hyperplasia
por: Kolli, Vipula, et al.
Publicado: (2020) -
Graves’ Disease Presenting as Adrenal Crisis in a Patient With Congenital Adrenal Hyperplasia
por: Ibraheem Hamad, Mohammad Khair Ahmad, et al.
Publicado: (2021)